A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova and Lovaza in Men and Women With a History of Pancreatitis
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2016
Price : $35 *
At a glance
- Drugs Omega-3 carboxylic acids (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Hypertriglyceridaemia
- Focus Pharmacokinetics
- Acronyms ECLIPSEIV
- Sponsors AstraZeneca; Omthera Pharmaceuticals
- 29 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 16 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov